HIGHLIGHTS
- who: October and colleagues from the Shenyang Pharmaceutical University, China have published the research: Caffeine in liver diseases: Pharmacology and toxicology, in the Journal: (JOURNAL) of 19/07/2022
- what: This study examined the beneficial use of caffeine in different liver diseases and its toxity.
- how: The results showed that after 8-12 weeks of treatment the levels of serum alanine aminotransferase (ALT) aspartate transaminase (AST) hyaluronic acid (HA) laminin (LN) N-terminal peptide of type III procollagen (PIIINP) and type IV collagen in the high-dose group were significantly reduced. The results . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.